Sixteen-year follow-up of the cemented spectron femoral stem for hip arthroplasty.
Clinical and radiographic follow-up was performed on a consecutive series of 105 patients who underwent 120 total hip arthroplasties at the authors' institution from 1983 to 1988 with a straight, cobalt-chrome femoral stem implanted using a second-generation cementing technique. The mean age at the time of surgery was 68.5 years, and the mean follow-up was 16 years. At 16 years' follow-up, the prevalence of revision for aseptic loosening of the Spectron femoral component was only 4.2%; 5 stems were revised for aseptic loosening at a mean of 10.2 years after implantation. Sixteen-year survivorship of the component was 93.9% +/- 2.7% when revision for aseptic loosening was taken as the endpoint or 90.3% +/- 4.4% when either revision for aseptic loosening or radiographic evidence of loosening was taken as the endpoint.
Issack
Paul S
PS
New York University Hospital for Joint Diseases Department of Orthopaedic Surgery, New York, NY, USA.
Botero
Herman G
HG
Hiebert
Rudi N
RN
Bong
Matthew R
MR
Stuchin
Steven A
SA
Zuckerman
Joseph D
JD
Di Cesare
Paul E
PE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D001672:Biocompatible Materials / Q000627:therapeutic use*; D001843:Bone Cements; D002858:Chromium Alloys / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011475:Prosthesis Failure; D012086:Reoperation
D001672:Biocompatible Materials; D001843:Bone Cements; D002858:Chromium Alloys